Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Trial Profile

Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CLARINET; CLARINET FORTE
  • Sponsors Ipsen
  • Most Recent Events

    • 03 Jul 2017 According to an Ipsen media release, Teijin Pharma has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen's subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET) based on results from this and phase II (J-001) trial.
    • 06 Jun 2017 Results of post hoc analysis of urinary 5HIAA and serum CgA data, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2017 According to an Ipsen media release, data evaluating correlation with tumor response and progression-free survival (PFS), will be presented at the American Society of Clinical Oncology (ASCO) 2017 conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top